You are here: Industry Insights > Sandoz

News List

Sandoz, Civica Rx Partner to Reduce Medicine Shortages in US Hospitals contractpharma
July 09, 2020
Sandoz to provide six injectable medicines used in acute care settings to help ensure supply reliability for optimal patient care.
Novartis terminates $1bn Sandoz US deal with Aurobindo pharmaceutical-technology
April 03, 2020
Novartis and Aurobindo Pharma USA have signed a mutual agreement to terminate their deal covering the Sandoz US generic oral solids and dermatology businesses.
Sandoz to keep prices stable for potential coronavirus drugs pharmaceutical-technology
March 03, 2020
Novartis subsidiary Sandoz has said that the company would keep prices stable for a basket of medicines, which may have the potential to treat patients infected by coronavirus.
Adamas Announces Settlement of Patent Litigation with Sandoz americanpharmaceuticalreview
January 03, 2020
Adamas has entered into a Settlement Agreement with Sandoz resolving its ongoing litigation concerning Sandoz’s Abbreviated New Drug Application (ANDA) seeking approval by ...
Sandoz voluntarily recalls ranitidine over NDMA contamination concerns europeanpharmaceuticalreview
September 27, 2019
The probable carcinogen N-nitrosodimethylamine was detected in Sandoz’s ranitidine capsules, prompting the voluntary move.
FDA announces voluntary recall of Sandoz ranitidine capsules following detection of an impurity worldpharmanews
September 26, 2019
The U.S. Food and Drug Administration is alerting health care professionals and patients of a voluntary recall of 14 lots of prescription ranitidine capsules distributed by Sandoz Inc. ...
Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine worldpharmanews
September 06, 2019
Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab biosimilar.
Sandoz licences proposed multiple sclerosis biosimilar from Polpharma pharmaceutical-technology
September 04, 2019
Novartis unit Sandoz has signed an agreement with biopharmaceutical firm Polpharma Biologics for exclusive rights to commercialise a proposed biosimilar of Biogen’s multiple sclerosis drug natalizumab.
Sandoz issues voluntary recall for medication bottles europeanpharmaceuticalreview
September 04, 2019
The pharmaceutical company has announced a recall for certain prescription drug bottles which do not meet child-resistant regulations.
Sandoz Recalls Losartan Potassium, Ezetimibe Prescription Bottles americanpharmaceuticalreview
September 03, 2019
Sandoz has voluntarily recalled losartan potassium and ezetimibe in prescription drug bottles in the U.S. due to failure to meet child-resistant closure requirements.

Previous page 1 2 3 4 5 6 7 8 Next page